<code id='A272F14939'></code><style id='A272F14939'></style>
    • <acronym id='A272F14939'></acronym>
      <center id='A272F14939'><center id='A272F14939'><tfoot id='A272F14939'></tfoot></center><abbr id='A272F14939'><dir id='A272F14939'><tfoot id='A272F14939'></tfoot><noframes id='A272F14939'>

    • <optgroup id='A272F14939'><strike id='A272F14939'><sup id='A272F14939'></sup></strike><code id='A272F14939'></code></optgroup>
        1. <b id='A272F14939'><label id='A272F14939'><select id='A272F14939'><dt id='A272F14939'><span id='A272F14939'></span></dt></select></label></b><u id='A272F14939'></u>
          <i id='A272F14939'><strike id='A272F14939'><tt id='A272F14939'><pre id='A272F14939'></pre></tt></strike></i>

          fashion

          fashion

          author:entertainment    Page View:71
          Tome cofounders Jonathan Gootenberg, left, and Omar Abudayyeh, a scientific team that's trying to reinvent gene editing for a new era of biotech innovation.
          Suzanne Kreiter/Globe staff

          WATERTOWN — Their brainstorming began in an MIT class in 2010 when the eager undergrads shot each other emails about how to solve a bioengineering equation. It has continued for 14 years over sushi dinners, between Marvel movies, and during rowing-machine workouts.

          Together, Omar Abudayyeh, 33, and Jonathan Gootenberg, 32, have probed the mysteries of genomic editing and COVID detection. They co-published 10 scientific papers, helped launch two medical-diagnostic companies, and cofounded a Watertown startup, Tome Biosciences, that reengineers genes and cells to cure diseases. They also run the Abudayyeh-Gootenberg Lab at Harvard.

          advertisement

          Gootenberg and Abudayyeh are an unusual pair, two scientists — a Jewish American and a Palestinian American — who prefer working together in a field that often draws solitary researchers and rewards individual achievement.

          Get unlimited access to award-winning journalism and exclusive events.

          Subscribe Log In

          explore

          As demand for Covid shots wanes, Moderna seeks its next success
          As demand for Covid shots wanes, Moderna seeks its next success

          RubyWallauforSTATModernachairmanNoubarAfeyanexudedstarpowerearlierthismonthashecommandedthespotlight

          read more
          Private equity deals in Medicare Advantage declines
          Private equity deals in Medicare Advantage declines

          AdobeMajorinsurancecompanieslikeUnitedHealthcareandHumanahaveedgedoutprivateequityfirmsfrominvesting

          read more
          Peter Hotez and the public health issue of online harassment
          Peter Hotez and the public health issue of online harassment

          AdobeFather’sDayweekendwasanythingbutcalmonTwitter,whicheruptedasvaccineexpertPeterHotezwaschallenge

          read more

          Medical mystery: When a cough is not just a cough

          MollyFergusonforSTATWhenCherylDaiglestartedcoughinginFebruary2013,shechalkedituptothesneezingandsnif